How did VinBrain come into existence?
After 26 years abroad, spending 13 years as the Director of Engineering and AI Innovation at Microsoft in the United States, I returned to Vietnam. my homeland, in 2019. The founding of VinBrain can be traced back to a series of coincidental events that occurred at that time, nearly five years ago.
Witnessing my mother's stroke firsthand on one back-home occasion made me acutely aware of healthcare challenges in Vietnam. Leaving my 13-year leadership at Microsoft, I answered Vietnam's billionaire, Chair of Vingroup, Pham Nhat Vuong's call to build a global tech alliance with Vietnamese talents, fueled by ‘forever the entrepreneurship spirit’. Consequently, the firm determination of 18 like-minded talents beside me, who bred the seed of VinBrain in 2019, led us on a mission to alleviate patient suffering and relieve the overburdened healthcare workforce through advanced AI technologies. We aspired to build a health tech company where the core technology was developed by Vietnamese talents, breaking away from the conventional practice of importing solutions from overseas. ‘Infuse AI and IoT to improve people's lives and productivity’ is the company's mission to streamline all its efforts and activities and enable diagnostic radiology and digital healthcare transformation to accelerate to the next level of excellence.
What are the key technological advancements that have propelled VinBrain's position as a leader in AI solutions for healthcare?
Diese Geschichte stammt aus der BioSpectrum Asia Feb 2024-Ausgabe von BioSpectrum Asia.
Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.
Bereits Abonnent ? Anmelden
Diese Geschichte stammt aus der BioSpectrum Asia Feb 2024-Ausgabe von BioSpectrum Asia.
Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.
Bereits Abonnent? Anmelden
Inventia announces groundbreaking advancement in 3D cell culture technology
Inventia Life Science, an innovator in 3D cell culture technologies, has announced the launch of RASTRUM Allegro, a groundbreaking advancement in 3D cell culture technology designed to accelerate drug discovery and disease research with unprecedented scalability, reproducibility, and efficiency.
Aphra names Justin Untersteiner as CEO
The Australian Health Practitioner Regulation Agency (Ahpra) has appointed Justin Untersteiner as Chief Executive Officer (CEO).
WHO partners with Siriraj Hospital in Thailand to address growing burden of injuries and falls
The World Health Organization (WHO) has signed a Memorandum of Understanding (MoU) with Siriraj Hospital, Mahidol University, Thailand, to strengthen collaboration on trauma, injury, and fall prevention across the WHO South-East Asia Region to address the growing health, social, and economic challenges posed by these issues.
Jubilant Biosys expands footprint in Europe for Biologics and Antibody Drug Conjugate services
Jubilant Biosys Innovative Research Services Pte Limited, Singapore (JBIRSPL), a subsidiary of Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova Limited, has executed the transaction definitive agreements with Pierre Fabre (PF) SA, and its affiliate entities, for JBIRSPL to acquire 80 per cent equity capital in JASMIN (new company incorporated by PF in France, as a Société par Actions Simplifiée (SAS)), with remaining 20 per cent retained by PF.
PanopticAI gets US FDA clearance for contactless vital signs monitoring software
PanopticAI, a startup in remote patient monitoring space, has received 510(k) clearance from the US Food and Drug Administration (FDA) for its contactless vital signs monitoring software.
Immuneel unveils India's first global CAR T-cell therapy for Non-Hodgkin's Lymphoma
In a significant step forward for India’s cancer treatment, Immuneel Therapeutics has unveiled Qartemi, country’s first global CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL), a group of blood cancers.
Axel Klarmeyer joins as CEO at Chamlion International
China-based Chamlion, a pioneer in integrated dental 3D printing solutions, has announced the appointment of Axel Klarmeyer as the Chief Executive Officer (CEO) of Chamlion International, overseeing the company's international business operations.
World Bank supports Bosnia and Herzegovina in strengthening healthcare
The World Bank’s Board of Executive Directors has approved a $75 million Second Health Sectors Programmatic Development Policy Loan for Bosnia and Herzegovina (BiH).
GHIT announces $12.7 M worth investment for developing diagnostics and drugs for malaria, NTDs
The Global Health Innovative Technology (GHIT) Fund, headquartered in Japan, has announced a total investment of approximately JPY 2 billion ($12.7 million) in eight projects for the development of new diagnostics and drugs for neglected tropical diseases (NTDs) and malaria.
NIH to lead implementation of National Plan to End Parkinson's Act in US
With support from the US Department of Health and Human Services (HHS) Office of the Assistant Secretary for Health (OASH), the National Institutes of Health (NIH) is leading the implementation of the Dr. Emmanuel Bilirakis and Jennifer Wexton National Plan to End Parkinson’s Act, which was signed into law on July 2, 2024.
